[ad_1]
Noubar Afeyan discusses potential for coronavirus booster on “The Claman Countdown”
Moderna, a leading supplier of COVID-19 vaccines, is expected to join the S&P 500, the broadest metric in the U.S. stock market.
Shares surged on Friday, adding to its annual gain of more than 148%.
| Teleprinter | security | Last | Switch | Switch % |
|---|---|---|---|---|
| MRNA | MODERN, INC. | 285.59 | +25.91 | + 9.98% |
Inclusion can force investors in mutual funds that mirror the benchmark to buy the stock, which can often generate additional gains.
RETAIL SALES INCREASE AS ECONOMY Gains Momentum
The biotech company, which has already shipped more than 100 million COVID-19 vaccines, will replace Alexion Pharmaceuticals Inc., which will be acquired by AstraZeneca on July 21 according to S&P Dow Jones indices.
CLICK HERE TO LEARN MORE ABOUT FOX BUSINESS
| Teleprinter | security | Last | Switch | Switch % |
|---|---|---|---|---|
| ALXN | ALEXION PHARMACEUTICALS, INC. | 180.64 | +0.13 | + 0.07% |
| AZN | ASTRAZENECA SA | 57.03 | +0.07 | + 0.12% |
Moderna is on track to deliver 1 billion doses of COVID-19 vaccine this year and aims to increase that number by 2022 to 3 billion doses.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
[ad_2]
Source link